×
About 14,889,585 results

DFS Improvement Falls Short With Anti–PD-L1 in Muscle-Invasive Urothelial Cancer
https://www.targetedonc.com/view/dfs-improvement-not-significant-with-anti-pd-l1-in-muscle-invasive-urothelial-cancer

May 31st, 2020 - Adjuvant treatment with anti–PD-L1 therapy demonstrated a numerically increased but not statistically significant improvement in disease-free survival (DFS) compared with observation in patients with muscle-invasive urothelial carcinoma (MIUC) in a primary analysis presented at the 2020 American Society of Clinical Oncology Virtual Scientific Program. DFS was the primary end point of the IMvigo...

Investigation of Tepotinib Shows Durable Benefit in NSCLC With a METex14 Skipping Mutation May 31, 2020
https://www.targetedonc.com/view/investigation-of-tepotinib-shows-durable-benefit-in-nsclc-with-a-metex14-skipping-mutation

May 31st, 2020 - Durable clinical activity was demonstrated with tepotinib, an oral, highly selective MET inhibitor, in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) and a MET exon 14 (METex14) skipping mutation identified through liquid or tissue biopsy. This data was from the phase 2 VISION trial (NCT02864992) presented during the at the 2020 Virtual Scientific Meeting and pu...

Key Efficacy End Points Upheld at 3 Years for Cemiplimab in CSCC
https://www.targetedonc.com/view/key-efficacy-end-points-upheld-at-3-years-for-cemiplimab-in-cscc

May 31st, 2020 - Three-year follow-up data from the phase 2 EMPOWER-CSCC-1 trial (NCT02760498) demonstrated a clinically meaningful survival and duration of response (DOR) improvement with cemiplimab-rwlc (Libtayo) in patients with advanced cutaneous squamous cell carcinoma (CSCC).

Pralsetinib Demonstrates Significant Findings in RET+ Solid Tumors as FDA Grants Priority Review
https://www.targetedonc.com/view/pralsetinib-demonstrates-significant-findings-in-ret-solid-tumors-as-fda-grants-priority-review

May 31st, 2020 - Pralsetinib (BLU-667) demonstrated significant efficacy across various advanced solid tumor types harboring RET alterations, including in patients with difficult-to-treat cancers, according to findings from a subgroup of the ongoing phase 1/2 ARROW trial (NCT03037385) presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.

Statistical Analyses Confirm Benefit of Cabazitaxel Over Abiraterone or Enzalutamide in mCRPC
https://www.targetedonc.com/view/statistical-analyses-confirm-benefit-of-cabazitaxel-over-abiraterone-or-enzalutamide-in-mcrpc

May 31st, 2020 - Stratified multivariate analysis as well as efficacy from multiple treatment time points confirmed the benefit of cabazitaxel (Jevtana) over abiraterone acetate (Zytiga) or enzalutamide (Xtandi) as a standard treatment in men with metastatic castration-resistant prostate cancer (mCRPC) who were previously treated with docetaxel and either of those 2 androgen receptor (AR)-targeted agents, accor...

Updated Data Displays Better OS With Use of Alectinib Over Crizotinib in ALK+ NSCLC
https://www.targetedonc.com/view/updated-data-displays-better-os-with-use-of-alectinib-over-crizotinib-in-alk-nsclc

May 31st, 2020 - Patients with ALK-positive non–small cell lung cancer (NSCLC) showed clinically meaningful improvement in overall survival (OS) when receiving alectinib (Alecensa), a highly selective second-generation TKI, versus those treated with crizotinib (Xalkori), according to updated data from the pivotal phase 3 ALEX trial presented at the 2020 ASCO Virtual Scientific Program.

5-Year Follow-Up of COMBI-AD Confirms Long-Term RFS Benefit With Dabrafenib/Trametinib in BRAF+ Melanoma
https://www.onclive.com/conference-coverage/asco-2020/5year-followup-of-combiad-confirms-longterm-rfs-benefit-with-dabrafenib-and-trametinib

May 30th, 2020 - Findings from a 5-year analysis of the phase 3 COMBI-AD trial validated the long-term benefit of adjuvant dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with resected, stage III BRAF V600E/K-mutant melanoma.

Dr. Van Tine on Next Steps With ADP-A2M4 in Advanced Solid Tumors
https://www.onclive.com/conference-coverage/asco-2020/dr-van-tine-on-next-steps-with-adpa2m4-in-advanced-solid-tumors

May 30th, 2020 - Brian A. Van Tine, MD, PhD, associate professor in the Department of Medicine, director, Sarcoma Program, Division of Medical Oncology, Washington University School of Medicine in St. Louis, discusses next steps with ADP-A2M4 SPEAR T cells in advanced solid tumors.

Encorafenib/Binimetinib Combo Continues to Show Survival Benefits in BRAF V600-Mutant Melanoma
https://www.onclive.com/conference-coverage/asco-2020/encorafenibbinimetinib-combo-continues-to-show-survival-benefits-in-braf-v600mutant-melanoma

May 30th, 2020 - The combination of encorafenib (Braftovi) and binimetinib (Mektovi) demonstrated continuing benefit in overall survival (OS) and progression-free survival (PFS) for patients with BRAF V600–mutant melanoma, according to an updated analysis of the COLUMBUS (NCT01909453) trial during a poster presentation at the 2020 American Society of Clinical Oncology Virtual Scientific Program.

HERO Trial Suggests Relugolix to Become New Standard for T-Suppression in Advanced Prostate Cancer
https://www.onclive.com/conference-coverage/asco-2020/hero-trial-suggests-relugolix-to-become-new-standard-for-tsuppression-in-advanced-prostate-cancer

May 30th, 2020 - Relugolix (Relumina) demonstrated superiority over leuprolide (Lupron) in sustained testosterone (T)-suppression through 48 weeks, fast T-recovery after discontinuation, and a 50% reduction in major adverse cardiovascular events (MACE) in patients with advanced prostate cancer, according to findings from the phase 3 HERO trial, presented at the 2020 ASCO Virtual Scientific Meeting.

Frontline Pembrolizumab/Axitinib Survival Benefit Upholds in Advanced RCC
https://www.onclive.com/conference-coverage/asco-2020/frontline-pembrolizumabaxitinib-survival-benefit-upholds-in-advanced-rcc

May 30th, 2020 - The combination of pembrolizumab (Keytruda) and axitinib (Inlyta) continued to demonstrate a clinically significant improvement in progression-free and overall survival (OS) compared with sunitinib (Sutent) in patients with previously untreated, advanced renal cell carcinoma (RCC), according to updated findings of the phase 3 KEYNOTE-426 trial that were presented during the 2020 ASCO Virtual Sc...

Interim ZUMA-5 Analysis Shows Promise for Axi-Cel in Relapsed/Refractory iNHL
https://www.onclive.com/conference-coverage/asco-2020/interim-analysis-from-phase-ii-zuma5-study-shows-promise-for-axicel-in-rr-inhl

May 30th, 2020 - An interim analysis of the phase II ZUMA-5 study indicated that axicabtagene ciloleucel (axi-cel; Yescarta) demonstrated significant and durable clinical benefit, with high rates of overall response rate (ORR) and complete response (CR) observed, as well as a manageable safety profile in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

Frontline Durvalumab Maintains OS Benefit in Extensive-Stage Small Cell Lung Cancer
https://www.onclive.com/conference-coverage/asco-2020/frontline-durvalumab-maintains-os-benefit-in-updated-essclc-findings

May 30th, 2020 - The addition of durvalumab (Imfinzi) to standard chemotherapy continued to demonstrate an improvement in overall survival (OS) for patients with treatment-naïve extensive-stage small cell lung cancer (ES-SCLC), according to updated results from the phase 3 CASPIAN study presented at the 2020 American Society of Clinical Oncology Virtual Scientific Program.

KTE-X19 Demonstrates Comparable Pharmacologic, Clinical Outcomes to Approved Therapies in MCL
https://www.onclive.com/conference-coverage/asco-2020/ktex19-demonstrates-comparable-pharmacologic-clinical-outcomes-to-approved-therapies-in-mcl

May 30th, 2020 - The pharmacodynamic profile of KTE-X19, an autologous anti-CD19 CAR T-cell therapy, was associated with efficacy and treatment-related neurological events among patients with relapsed/refractory mantle cell lymphoma treated within the ZUMA-2 trial, according to data presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.

Mirvetuximab Soravtansine Combination Shows Positive Response, Tolerability in Ovarian Cancer
https://www.onclive.com/conference-coverage/asco-2020/mirvetuximab-soravtansine-combination-shows-positive-response-tolerability-in-ovarian-cancer

May 30th, 2020 - Mirvetuximab soravtansine in combination with bevacizumab (Avastin) to treat patients with platinum-agnostic ovarian cancer demonstrated encouraging overall response rates (ORRs) regardless of platinum status with a favorable tolerability profile, according to a study presented at the 2020 ASCO Virtual Scientific Program.

Tislelizumab Frontline Combos Extend PFS in Squamous NSCLC
https://www.onclive.com/conference-coverage/asco-2020/tislelizumab-frontline-combos-extend-pfs-in-squamous-nsclc

May 30th, 2020 - Combining the anti–PD-1 agent tislelizumab (BGB-A317) with chemotherapy improved progression-free survival (PFS) compared with chemotherapy alone as a frontline treatment in Chinese patients with advanced squamous non–small cell lung cancer (NSCLC), according to findings from the phase 3 BGB-A317-307 trial presenting during the 2020 ASCO Virtual Scientific Program.

Update Sustains OS Benefit With Encorafenib/Cetuximab Regimens in BRAF+ mCRC
https://www.onclive.com/conference-coverage/asco-2020/update-sustains-os-benefit-with-encorafenibcetuximab-regimens-in-braf-mcrc

May 30th, 2020 - The latest results from the phase 3 BEACON CRC study continued to show an overall survival (OS) benefit for encorafenib (Braftovi) plus cetuximab (Erbitux) with or without binimetinib (Mektovi) compared with cetuximab plus irinotecan-containing regimens in patients with BRAF V600E–mutated metastatic colorectal cancer (mCRC).

Encorafenib/Cetuximab Combos Sustain OS Benefit in BRAF+ Metastatic Colorectal Cancer
https://www.targetedonc.com/view/encorafenib-cetuximab-combos-sustain-os-benefit-in-braf-metastatic-colorectal-cancer

May 30th, 2020 - Encorafenib (Braftovi) plus cetuximab (Erbitux) with or without binimetinib (Mektovi) continued to show an overall survival benefit compared with cetuximab plus irinotecan-based regimens as treatment of patients with BRAF-mutated metastatic colorectal cancer (mCRC) in the updated findings from the phase 3 BEACON CRC clinical trial.

HER2+ Colorectal and Gastric/GEJ Cancers Demonstrate Responses to Fam-Trastuzumab Deruxtecan Therapy
https://www.targetedonc.com/view/her2-colorectal-and-gastric-gej-cancers-demonstrate-responses-to-fam-trastuzumab-deruxtecan

May 30th, 2020 - Data from 2 phase 2 trials involving fam-trastuzumab deruxtecan-nxki (Enhertu) revealed the agent’s ability to induce responses in patients with HER2-positive metastatic colorectal cancer (CRC) and advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Both studies had results presented at the 2020 ASCO Virtual Scientific Program.

Teclistamab Appears Safe, Efficacious in Relapsed/Refractory Multiple Myeloma
https://www.targetedonc.com/view/teclistamab-appears-safe-efficacious-in-relapsed-refractory-multiple-myeloma

May 30th, 2020 - Teclistamab (JNJ-64007957) may be a safe and efficacious treatment option for patients with relapsed/refractory multiple myeloma, according to findings from a phase I study presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.